Revolution Medicines (RVMD) said Wednesday the first patient has been dosed in a phase 3 trial evaluating daraxonrasib in patients with previously treated, locally advanced or metastatic RAS mutant non-small cell lung cancer compared to docetaxel chemotherapy.
The trial is expected to enroll around 420 patients, with dual primary endpoints of progression-free survival and overall survival, the company said.
The decision to evaluate daraxonrasib as a monotherapy was informed by early evidence from a single-arm trial showing that the compound had an acceptable safety profile and encouraging antitumor activity, the company said.
Revolution Medicines' shares rose by more than 2% in premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。